Overactive Bladder Treatment
On this page
Direct answer
Overactive bladder (OAB) is urgency, with or without urge incontinence, usually with frequency and nocturia, in the absence of infection or metabolic disease; treatment climbs a ladder. First come conservative measures — fluid discipline, caffeine reduction, weight loss and bladder training — then antimuscarinics or the beta-3 agonist mirabegron; refractory cases go to third-line options: intradetrusor botulinum toxin (about 100 units, with a real risk of retention needing self-catheterisation), percutaneous tibial nerve stimulation (twelve weekly sessions), or sacral neuromodulation, with bladder augmentation as the last resort. In older patients, anticholinergic burden on cognition decides drug choice, favouring trospium or mirabegron over oxybutynin.
What you must remember
- Diagnosis is symptomatic (urgency is the indispensable symptom) after excluding UTI, diabetes, atrophic vaginitis in women and bladder pathology where indicated.
- Conservative core: total fluid about 1.5-2 L daily, caffeine and alcohol reduction, weight loss, supervised bladder training with progressive voiding intervals.
- Antimuscarinics (oxybutynin, tolterodine, solifenacin, fesoterodine, trospium) block M3-mediated detrusor contraction; dry mouth and constipation are the commonest limiting effects.
- Oxybutynin has the highest central nervous system penetration — avoid in the elderly and in dementia; trospium (quaternary amine) and darifenacin are more bladder-selective alternatives.
- Mirabegron, a beta-3 adrenergic agonist, relaxes detrusor smooth muscle with less cognitive cost; monitor blood pressure; combination with solifenacin outperforms either alone in trials.
- Botulinum toxin A intradetrusor injection (commonly 100 units in idiopathic OAB) helps a majority for six to nine months; complications are urinary tract infection in a fifth or so and retention requiring clean intermittent catheterisation in perhaps 5-10 per cent — consent must cover teaching self-catheterisation.
- PTNS: 30-minute weekly sessions for twelve weeks via the posterior tibial nerve; sacral neuromodulation involves a staged test then implant.
- In the neurogenic bladder, the same ladder sits under the extra goal of lowering storage pressure to protect the kidneys.
Climbing the ladder in an older patient
A 68-year-old woman has urgency, eight voids by day and two at night, with occasional large leaks; urinalysis is clear, post-void residual normal. Step one is a bladder diary — it frequently reveals 3 litres of tea daily — plus fluid and caffeine counselling and bladder training over six to twelve weeks. Step two is a drug: solifenacin 5 mg or mirabegron, particularly here because she is on polypharmacy and anticholinergic load matters for cognition; review at four to six weeks for effect, dry mouth and constipation, and constipation should be managed pre-emptively or it sabotages adherence.
If two adequate drug trials fail, step three is a shared decision. Botulinum toxin offers the strongest effect but obliges her to accept a small risk of retaining and needing self-catheterisation — she should meet the catheter teaching team before consenting. PTNS is the gentle option needing twelve clinic visits with negligible risk; neuromodulation suits selected, motivated patients with a successful test phase. The examinable discipline is not memorising the ladder but the checks between rungs: residual volume before antimuscarinics (existing retention worsens), blood pressure with mirabegron, and cognition review in every older patient on antimuscarinics — the Beers-criteria logic that has made oxybutynin a poor answer in a 80-year-old.
Where students slip
The classic wrong answer treats OAB as an infection or a small bladder and orders scan after scan; the syndrome is clinical, and imaging is selective. The second slip is oxybutynin prescribed reflexively to elderly patients with dementia — the question stem naming dementia is bait for exactly that error, and the scored answer names mirabegron or a peripherally restricted agent. The third is consent for botulinum toxin without mentioning self-catheterisation: in viva, that omission alone fails the station, because temporary retention is a common, foreseeable outcome of an effective injection.
Frequently asked questions
What defines overactive bladder?
Urgency, with or without urge incontinence, usually with frequency and nocturia, once urinary infection and metabolic causes are excluded — urgency is the essential symptom.
Which antimuscarinic is best avoided in elderly patients?
Oxybutynin, because it crosses the blood-brain barrier and is associated with confusion and cognitive decline; trospium or mirabegron are preferred in patients with dementia risk.
What are the key risks of intradetrusor botulinum toxin?
Urinary tract infection in roughly a fifth of patients and urinary retention needing clean intermittent catheterisation in about 5-10 per cent; the effect lasts six to nine months and repeats are usual.
What is percutaneous tibial nerve stimulation?
Neuromodulation through a needle electrode near the posterior tibial nerve, given as 30-minute weekly sessions for twelve weeks, a low-risk third-line option for refractory OAB.
Can antimuscarinics and mirabegron be combined?
Yes — solifenacin plus mirabegron is an established combination with better efficacy than either alone, used after monotherapy fails, with blood pressure monitoring.